טוען...
Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
BACKGROUND: Certolizumab pegol is used to treat ankylosing spondylitis, Crohn’s disease, psoriatic arthritis, and rheumatoid arthritis. Unlike other monoclonal antibodies such as infliximab and adalimumab, certolizumab does not contain an Fc fraction and hence does not induce complement activation....
שמור ב:
| הוצא לאור ב: | Balkan Med J |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Galenos Publishing
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6158467/ https://ncbi.nlm.nih.gov/pubmed/29687787 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4274/balkanmedj.2017.1224 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|